Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy

Open Access 14-05-2024 | Progressive Supranuclear Palsy | REVIEW

Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review

Authors: Elise E. Dunning, Boris Decourt, Nasser H. Zawia, Holly A. Shill, Marwan N. Sabbagh

Published in: Neurology and Therapy

Login to get access

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most representative forms of tauopathy. PSP presents in several different phenotypic variations and is often accompanied by the development of concurrent neurodegenerative disorders. PSP is universally fatal, and effective disease-modifying therapies for PSP have not yet been identified. Several tau-targeting treatment modalities, including vaccines, monoclonal antibodies, and microtubule-stabilizing agents, have been investigated and have had no efficacy. The need to treat PSP and other tauopathies is critical, and many clinical trials investigating tau-targeted treatments are underway. In this review, the PubMed database was queried to collect information about preclinical and clinical research on PSP treatment. Additionally, the US National Library of Medicine’s ClinicalTrials.gov website was queried to identify past and ongoing clinical trials relevant to PSP treatment. This narrative review summarizes our findings regarding these reports, which include potential disease-modifying drug trials, modifiable risk factor management, and symptom treatments.
Literature
1.
2.
Giagkou N, Hoglinger GU, Stamelou M. Progressive supranuclear palsy. Int Rev Neurobiol. 2019;149:49–86.PubMedCrossRef
3.
Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736–43.PubMedPubMedCentralCrossRef
4.
Fleury V, Brindel P, Nicastro N, Burkhard PR. Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism Relat Disord. 2018;54:30–9.PubMedCrossRef
5.
Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord. 2004;19(10):1239–40.PubMedCrossRef
6.
Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001;124(Pt 7):1438–49.PubMedCrossRef
7.
Swallow DMA, Counsell CE. Prevalence of progressive supranuclear palsy and corticobasal syndrome in Scotland. Neuroepidemiology. 2022;56(4):291–7.PubMedCrossRef
8.
Zermansky A, Ben-Shlomo Y. Epidemiology of progressive supranuclear palsy and multiple system atrophy. In: Litvan I, editor. Atypical parkinsonian disorders. Totowa: Humana; 2005. p. 23–31.CrossRef
9.
Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101(4):1371–8.PubMedCrossRef
10.
Bowles KR, Pugh DA, Oja LM, et al. Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD. Acta Neuropathol. 2022;143(2):225–43.PubMedCrossRef
11.
Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8(2):393–9.PubMedPubMedCentralCrossRef
12.
13.
Przewodowska D, Marzec W, Madetko N. Novel therapies for parkinsonian syndromes-recent progress and future perspectives. Front Mol Neurosci. 2021;14:720220.PubMedPubMedCentralCrossRef
14.
Monzio Compagnoni G, Di Fonzo A. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathol Commun. 2019;7(1):113.PubMedPubMedCentralCrossRef
15.
16.
Jabbari E, Koga S, Valentino RR, et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurol. 2021;20(2):107–16.PubMedCrossRef
17.
Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16(7):552–63.PubMedPubMedCentralCrossRef
18.
Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699–705.PubMedPubMedCentralCrossRef
19.
Sanchez-Contreras MY, Kouri N, Cook CN, et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener. 2018;13(1):37.PubMedPubMedCentralCrossRef
20.
Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112–9.PubMedCrossRef
21.
Wray S, Saxton M, Anderton BH, Hanger DP. Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem. 2008;105(6):2343–52.PubMedCrossRef
22.
Irwin DJ, Cohen TJ, Grossman M, et al. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain. 2012;135(Pt 3):807–18.PubMedPubMedCentralCrossRef
23.
Schmidt ML, Schuck T, Sheridan S, et al. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol. 2001;159(3):937–43.PubMedPubMedCentralCrossRef
24.
25.
Samimi N, Sharma G, Kimura T, et al. Distinct phosphorylation profiles of tau in brains of patients with different tauopathies. Neurobiol Aging. 2021;108:72–9.PubMedCrossRef
26.
27.
28.
Polanco JC, Scicluna BJ, Hill AF, Gotz J. Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. J Biol Chem. 2016;291(24):12445–66.PubMedPubMedCentralCrossRef
29.
30.
Alavi Naini SM, Soussi-Yanicostas N. Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med Cell Longev. 2015;2015:151979.PubMedPubMedCentralCrossRef
31.
Borza LR. A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases. Rev Med Chir Soc Med Nat Iasi. 2014;118(1):19–27.PubMed
32.
Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002;156(6):1051–63.PubMedPubMedCentralCrossRef
33.
Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Investig. 2007;117(1):236–45.PubMedCrossRef
34.
Kim SY, Kim TB, Moon KA, et al. Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo. Exp Mol Med. 2008;40(4):461–76.PubMedPubMedCentralCrossRef
35.
Giannopoulos PF, Chu J, Sperow M, et al. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry. 2015;78(10):693–701.PubMedPubMedCentralCrossRef
36.
Maphis N, Xu G, Kokiko-Cochran ON, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138(Pt 6):1738–55.PubMedPubMedCentralCrossRef
37.
Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68(1):19–31.PubMedPubMedCentralCrossRef
38.
Usenovic M, Niroomand S, Drolet RE, et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J Neurosci. 2015;35(42):14234–50.PubMedPubMedCentralCrossRef
39.
40.
Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–9.PubMedCrossRef
41.
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140(2):99–119.PubMedPubMedCentralCrossRef
42.
Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7.PubMedCrossRef
43.
Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86(3):244–50.PubMedCrossRef
44.
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–89.PubMedCrossRef
45.
Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116–26.PubMedPubMedCentralCrossRef
46.
Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–85.PubMedPubMedCentralCrossRef
47.
Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216–25.PubMedPubMedCentralCrossRef
48.
Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003;210(1–2):57–60.PubMedCrossRef
49.
Adachi M, Kawanami T, Ohshima H, Sugai Y, Hosoya T. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci. 2004;3(3):125–32.PubMedCrossRef
50.
Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1754–62.PubMedCrossRef
51.
Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246(1):214–21.PubMedCrossRef
52.
Quattrone A, Morelli M, Williams DR, et al. MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism. Neurology. 2016;87(12):1266–73.PubMedPubMedCentralCrossRef
53.
Nigro S, Arabia G, Antonini A, et al. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. Eur Radiol. 2017;27(6):2665–75.PubMedCrossRef
54.
Alster P, Migda B, Madetko N, et al. The role of frontal assessment battery and frontal lobe single-photon emission computed tomography in the differential diagnosis of progressive supranuclear palsy variants and corticobasal syndrome—a pilot study. Front Neurol. 2021;12: 630153.PubMedPubMedCentralCrossRef
55.
Alster P, Nieciecki M, Koziorowski D, et al. Is brain perfusion a differentiating feature in the comparison of progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS)? J Clin Neurosci. 2020;77:123–7.PubMedCrossRef
56.
Alster P, Nieciecki M, Koziorowski DM, et al. Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (Baltimore). 2019;98(30):e16603.PubMedCrossRef
57.
Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270–9.PubMedCrossRef
58.
Owens E, Josephs KA, Savica R, et al. The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol. 2016;263(12):2419–23.PubMedCrossRef
59.
Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: a review. Clin Parkinson Relat Disord. 2019;1:66–71.CrossRef
60.
Rusina R, Bajtosova R, Csefalvay Z, et al. Comorbid neurodegeneration in primary progressive aphasia: clinicopathological correlations in a single-center study. Behav Neurol. 2022;2022:6075511.PubMedPubMedCentralCrossRef
61.
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9.PubMedCrossRef
62.
Rabadia SV, Litvan I, Juncos J, et al. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019;66:166–70.PubMedCrossRef
63.
Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Hoglinger GU. Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol. 2021;12: 637176.PubMedPubMedCentralCrossRef
64.
Bharadwaj P, Wijesekara N, Liyanapathirana M, et al. The link between type 2 diabetes and neurodegeneration: roles for amyloid-β, amylin, and tau proteins. J Alzheimers Dis. 2017;59(2):421–32.PubMedCrossRef
65.
Alster P, Dunalska A, Migda B, Madetko N, Krolicki L. The rate of decrease in brain perfusion in progressive supranuclear palsy and corticobasal syndrome may be impacted by glycemic variability—a pilot study. Front Neurol. 2021;12: 767480.PubMedPubMedCentralCrossRef
66.
67.
Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW. A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol. 2002;59(10):1597–601.PubMedCrossRef
68.
Koga S, Roemer SF, Kasanuki K, Dickson DW. Cerebrovascular pathology presenting as corticobasal syndrome: an autopsy case series of “vascular CBS.” Parkinsonism Relat Disord. 2019;68:79–84.PubMedPubMedCentralCrossRef
69.
Chang JK, Leso A, Subaiea GM, et al. Tolfenamic acid: a modifier of the tau protein and its role in cognition and tauopathy. Curr Alzheimer Res. 2018;15(7):655–63.PubMedPubMedCentralCrossRef
70.
Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18(9):42.PubMedPubMedCentralCrossRef
71.
Pilotto A, Rizzetti MC, Lombardi A, et al. Cerebellar rTMS in PSP: a double-blind sham-controlled study using mobile health technology. Cerebellum. 2021;20(4):662–6.PubMedPubMedCentralCrossRef
72.
Scelzo E, Lozano AM, Hamani C, et al. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):613–6.PubMedCrossRef
73.
Clerici I, Ferrazzoli D, Maestri R, et al. Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS One. 2017;12(2):e0170927.PubMedPubMedCentralCrossRef
74.
Sale P, Stocchi F, Galafate D, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. Front Hum Neurosci. 2014;8:207.PubMedPubMedCentralCrossRef
75.
Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4.PubMedCrossRef
76.
Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.PubMedCrossRef
77.
Novak P, Pimentel Maldonado DA, Novak V. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study. PLoS One. 2019;14(4):e0214364.PubMedPubMedCentralCrossRef
78.
Khanna MR, Kovalevich J, Lee VM, Trojanowski JQ, Brunden KR. Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimers Dement. 2016;12(10):1051–65.PubMedCrossRef
79.
Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601–11.PubMedPubMedCentralCrossRef
80.
Cleveland DW, Connolly JA, Kalnins VI, Spiegelman BM, Kirschner MW. Physical properties and cellular localization of tau, a microtubule-associated protein which induces assembly of purified tubulin. J Cell Biol. 1977;75:A283.
81.
Cleveland DW, Hwo SY, Kirschner MW. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol. 1977;116(2):227–47.PubMedCrossRef
82.
Lee VM, Daughenbaugh R, Trojanowski JQ. Microtubule stabilizing drugs for the treatment of Alzheimer’s disease. Neurobiol Aging. 1994;15(Suppl 2):S87–9.PubMedCrossRef
83.
Magen I, Ostritsky R, Richter F, et al. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing alpha-synuclein. Pharmacol Res Perspect. 2014;2(5):e00065.PubMedPubMedCentralCrossRef
84.
Tsai RM, Miller Z, Koestler M, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(2):215–24.PubMedCrossRef
85.
Brunden KR, Yao Y, Potuzak JS, et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies. Pharmacol Res. 2011;63(4):341–51.PubMedCrossRef
86.
87.
Mudher A, Colin M, Dujardin S, et al. What is the evidence that tau pathology spreads through prion-like propagation? Act Neuropathol Commun. 2017;5(1):99.CrossRef
88.
Kondo A, Shahpasand K, Mannix R, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431–6.PubMedPubMedCentralCrossRef
89.
Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.PubMedPubMedCentralCrossRef
90.
Buchanan T, De Bruyn S, Fadini T, Watanabe S, Germani M, Mesa A, editors. A randomised, placebo-controlled, first-in-human study with a central tau epitope antibody–UCB0107. Int Congr Park Dis Mov Disord Nice; 2019 Sept 22–26, 2019.
91.
Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451–7.PubMedCrossRef
92.
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018;4:746–55.PubMedCrossRef
93.
Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549–58.PubMedCrossRef
94.
Hoglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182–92.PubMedCrossRef
95.
96.
West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236–41.PubMed
97.
Beck G, Yamashita R, Kido K, et al. An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau. Neuropathology. 2023;43(4):326–32.PubMedCrossRef
98.
Novak P, Zilka N, Zilkova M, et al. AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis. 2019;6(1):63–9.PubMed
99.
Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy. 2016;8(9):1119–34.PubMedCrossRef
100.
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–34.PubMedCrossRef
101.
Novak P, Schmidt R, Kontsekova E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:108.PubMedPubMedCentralCrossRef
102.
Vaz M, Silvestre S. Alzheimer’s disease: recent treatment strategies. Eur J Pharmacol. 2020;887:173554.PubMedCrossRef
103.
104.
Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8(8):e72301.PubMedPubMedCentralCrossRef
105.
106.
Harrington CR, Storey JM, Clunas S, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J Biol Chem. 2015;290(17):10862–75.PubMedPubMedCentralCrossRef
107.
Melis V, Magbagbeolu M, Rickard JE, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. 2015;26(4):353–68.PubMedPubMedCentralCrossRef
108.
Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2015;44(2):705–20.PubMedCrossRef
109.
Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996;93(20):11213–8.PubMedPubMedCentralCrossRef
110.
Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–84.PubMedPubMedCentralCrossRef
111.
Schelter BO, Shiells H, Baddeley TC, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2019;72(3):931–46.PubMedPubMedCentralCrossRef
112.
113.
Borghi R, Giliberto L, Assini A, et al. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology. 2002;58(4):589–92.PubMedCrossRef
114.
Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer’s disease related biomarkers. Neuropharmacology. 2014;79:596–602.PubMedPubMedCentralCrossRef
115.
Adwan L, Subaiea GM, Basha R, Zawia NH. Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies. J Neurochem. 2015;133(2):266–72.PubMedCrossRef
116.
Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8.PubMedCrossRef
117.
Leclair-Visonneau L, Rouaud T, Debilly B, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg. 2016;146:35–9.PubMedCrossRef
118.
Min SW, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21(10):1154–62.PubMedPubMedCentralCrossRef
119.
VandeVrede L, Dale ML, Fields S, et al. Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Mov Disord Clin Pract. 2020;7(4):440–7.PubMedPubMedCentralCrossRef
120.
121.
Ryan P, Xu M, Davey AK, et al. O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chem Neurosci. 2019;10(5):2209–21.PubMedCrossRef
122.
Bartolome-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature. Expert Opin Ther Pat. 2021;31(12):1117–54.PubMedCrossRef
123.
124.
DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.PubMedPubMedCentralCrossRef
125.
126.
Marras C, Cunningham CR, Hou J, et al. Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism Relat Disord. 2018;48:89–92.PubMedCrossRef
127.
128.
Arrant AE, Filiano AJ, Unger DE, Young AH, Roberson ED. Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia. Brain. 2017;140(5):1447–65.PubMedPubMedCentralCrossRef
129.
Mateo I, Gonzalez-Aramburu I, Pozueta A, et al. Reduced serum progranulin level might be associated with Parkinson’s disease risk. Eur J Neurol. 2013;20(12):1571–3.PubMedCrossRef
130.
Minami SS, Min SW, Krabbe G, et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer’s disease mouse models. Nat Med. 2014;20(10):1157–64.PubMedPubMedCentralCrossRef
131.
132.
Hebron ML, Algarzae NK, Lonskaya I, Moussa C. Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Abeta1-42 gene transfer models. Exp Neurol. 2014;251:127–38.PubMedCrossRef
133.
Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA. 1998;95(18):10896–901.PubMedPubMedCentralCrossRef
134.
Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res. 2002;69(3):418–26.PubMedCrossRef
135.
Kim TS, Lim HK, Lee JY, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2008;436(2):196–200.PubMedCrossRef
136.
Nash KR, Lee DC, Hunt JB Jr, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging. 2013;34(6):1540–8.PubMedPubMedCentralCrossRef
137.
Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27(5):1409–1421.e6.PubMedPubMedCentralCrossRef
138.
139.
140.
Krug L, Chatterjee N, Borges-Monroy R, et al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 2017;13(3):e1006635.PubMedPubMedCentralCrossRef
141.
Gentry EG, Henderson BW, Arrant AE, et al. Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration. J Neurosci. 2016;36(4):1316–23.PubMedPubMedCentralCrossRef
142.
Secor JD, Kotha SR, Gurney TO, et al. Novel lipid-soluble thiol-redox antioxidant and heavy metal chelator, N,N′-bis(2-mercaptoethyl)isophthalamide (NBMI) and phospholipase D-specific inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) attenuate mercury-induced lipid signaling leading to protection against cytotoxicity in aortic endothelial cells. Int J Toxicol. 2011;30(6):619–38.PubMedPubMedCentralCrossRef
143.
VandeVrede L, Ljubenkov PA, Rojas JC, Welch AE, Boxer AL. Four-repeat tauopathies: current management and future treatments. Neurotherapeutics. 2020;17(4):1563–81.PubMedPubMedCentralCrossRef
144.
Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. 2003;341(3):201–4.PubMedCrossRef
145.
Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266.PubMedPubMedCentralCrossRef
146.
Patel NK, Gill SS. GDNF delivery for Parkinson’s disease. Acta Neurochir Suppl. 2007;97(Pt 2):135–54.PubMedCrossRef
147.
Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci. 2010;30(18):6236–46.PubMedPubMedCentralCrossRef
148.
Ubhi K, Inglis C, Mante M, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol. 2012;234(2):405–16.PubMedPubMedCentralCrossRef
149.
Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156–71.PubMedCrossRef
150.
Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81(3):163–221.PubMedCrossRef
151.
Heiser V, Engemann S, Brocker W, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington’s disease by using an automated filter retardation assay. Proc Natl Acad Sci USA. 2002;99(Suppl 4):16400–6.PubMedPubMedCentralCrossRef
152.
Yoo MH, Hyun HJ, Koh JY, Yoon YH. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investig Ophthalmol Vis Sci. 2005;46(12):4780–7.CrossRef
153.
Caumont AS, Octave JN, Hermans E. Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells. J Neurochem. 2006;97(1):128–39.PubMedCrossRef
154.
Shortland PJ, Leinster VH, White W, Robson LG. Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. Eur J Neurosci. 2006;24(12):3343–53.PubMedCrossRef
155.
Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;2:CD001447.
156.
157.
Odetti P, Garibaldi S, Norese R, et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2000;59(5):393–7.PubMedCrossRef
158.
Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994;62(4):1631–4.PubMedCrossRef
159.
Canesi M, Giordano R, Lazzari L, et al. Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016;14(1):127.PubMedPubMedCentralCrossRef
160.
Giordano R, Canesi M, Isalberti M, et al. Safety and effectiveness of cell therapy in neurodegenerative diseases: take-home messages from a pilot feasibility phase I study of progressive supranuclear palsy. Front Neurosci. 2021;15: 723227.PubMedPubMedCentralCrossRef
161.
Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology. 2019;93(1):e77–87.PubMedPubMedCentralCrossRef
Metadata
Title
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review
Authors
Elise E. Dunning
Boris Decourt
Nasser H. Zawia
Holly A. Shill
Marwan N. Sabbagh
Publication date
14-05-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00614-9